Skip to content
OpenCapital
Get started

Eikon Therapeutics, Inc. EIKN Vesting Of Early Exercised Stock Options And Restricted Common Stock

Other financials

Income statement

See full
Operating income-$87.3M-22.3%
Net income-$83.0M-21.6%
EPS (diluted)-$2.46+90.9%

Balance sheet

See full
Cash & equivalents$161.2M-21.2%
Total debt$254.8M—
Total equity$550.7M+186%
Total assets$850.8M—

Cash flow

See full
Operating cash flow-$89.8M-64.7%
CapEx$262.0K-98.8%
Free cash flow-$90.1M-17.1%

Valuation

See full
Market cap$521.35M—

Where this comes from

Reported directly by Eikon Therapeutics, Inc. in its filing.

Tagged under the XBRL concept eikn:VestingOfEarlyExercisedStockOptionsAndRestrictedCommonStock.

The official record: Eikon Therapeutics, Inc. ’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Eikon Therapeutics, Inc. 's vesting of early exercised stock options and restricted common stock?
Eikon Therapeutics, Inc. (EIKN) reported vesting of early exercised stock options and restricted common stock of $35K in Q1 2026.